VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
CASICASI Pharmaceuticals, Inc.
$0.15$2M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksCASICash Flow

CASI Pharmaceuticals, Inc. (CASI) Cash Flow Statement

30Y historyFree accessUpdated daily

Persistent cash burn is highlighted by the absence of positive free cash flow over the last ten quarters, compounded by a lack of capital allocation flexibility.

CASI Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99Dec'98Dec'97Dec'96Dec'95
Cash from Operations0-29.22M-19.97M-21.09M-26.84M-25.89M-23.24M-28.58M-6.4M-6.02M-5.51M-4M-3.28M-2.21M-4.27M-4.96M-10.21M-20.71M-23.52M-20.77M-14.52M-16.41M-24.25M-45.53M-52.87M-44.25M-35.8M-12.5M-6.6M-2.2M-4.44M
Operating CF Margin %--102.41%-58.94%-48.92%-88.98%-170.97%-562.65%----11555.6%-16839.15%--330.52%-220.12%-134.29%-193.27%-277.02%-318.08%-301.33%-245.32%-3191.94%-1539.14%-3870.37%-2839.71%-1205.07%-716%-240.38%-137.5%-50%-616.67%
Operating CF Growth %0%-46.36%5.32%21.44%-3.69%-11.37%18.69%-346.47%-6.29%-9.24%-37.99%-21.97%-48.08%48.22%13.86%51.44%50.7%11.95%-13.23%-43.1%11.51%32.34%46.74%13.88%-19.5%-23.6%-186.4%-89.39%-200%50.45%-2.07%
Net Income-49.38M-39.26M-26.94M-40.26M-35.84M-47.51M-45.36M-27.47M-10.77M-9.45M-7.21M-26.2M-5.74M-14.55M-4.56M-8.1M-8.22M-23.86M-22.41M-49.89M-16.31M-12.62M-19.49M-39.02M-43.31M-48.79M-36.9M-13.5M-6.5M-4.8M-7.71M
Depreciation & Amortization02.33M3.74M2.42M1.81M1.96M2.15M1.67M117.78K66.45K68.38K48.18K17.39K20.46K38.12K70.36K95.11K319.23K-779.15K-469.13K155.02K773.77K930.77K1.51M1.38M1.08M900K700K300K200K200K
Stock-Based Compensation1.31M1.31M7.22M7.01M7.77M7.82M7.31M6.12M650.44K3M1.54M2.19M2.04M978.24K609.72K271.62K320.16K1.09M1.45M1.55M72.99K175K094.87K0000000
Deferred Taxes0000-5.2M-3.94M1.24M325.46K19.89K-5.67K-27.51K-11.76K-2.04M04.55M28.25K49.66K-402.07K-1.45M-1.61M-72.99K-175K0-3.13M0000000
Other Non-Cash Items48.07M5.63M3.83M16.39M7.83M19.1M6.97M553.57K7.48K26.31K74.95K19.71M2.04M10.04M-4.56M3.05M133.08K2.2M1.52M31.04M-3.24K-3.47M184.56K426.82K-20.29M732.76K300K0300K200K-3.03M
Working Capital Changes0771K-7.82M-6.65M-3.22M-3.32M4.45M-9.78M3.57M348.04K36K273.73K400.88K1.29M-352.12K-275.79K-2.59M-56.6K-1.85M-1.4M1.64M-1.09M-5.87M-5.41M9.35M2.74M-100K300K-700K2.2M6.1M
Change in Receivables0-5.21M2.83M-3.17M-5.16M-3.35M-1.29M00023.73K-23.73K669.31K1.26M817.71K536.41K593.25K21.45K-56.55K-72.28K-472.65K178.2K0-132.13K000000-2.5M
Change in Inventory05.83M-9.74M-4.23M-551K3.19M-4.41M-283K00-4.63M-10.16M-15.01M77.63K-2.78M-5.42M-264.73K1.1M-43.33M-47.94M-30.33M-34M0-7.21M0000002.7M
Change in Payables0-1.72M1.15M1.07M1.49M-1.54M4M-1.1M849.37K180.53K129.47K352.17K-102.39K51.52K-897.67K-617.6K-1.53M-1.05M-1.4M346.67K3.94M-2.25M0-5.78M000000200K
Cash from Investing011.24M-9.67M31.16M-20.69M-20.72M-28.06M-21.77M-934.7K-64.79K-25.4K-466.33K-42.98K-48.39K77.31K-1.59K7.5M10.84M12.56M-12.95M-4.4M-11.27M-2.84M2.38M21.42M-1.64M2.4M20.4M-8.7M-20M-210K
Capital Expenditures0-223K-204K-5.61M-15.5M-19.33M-14.02M-21.77M-934.7K-223.23K-25.4K-466.33K-42.98K-48.39K-6K-3.6K-2.89K-134.06K-106.72K-227.44K-248.68K-163.54K-32.72K-558.19K-985.78K-1.64M-1.9M-1.8M-1M-200K-210K
CapEx % of Revenue0%0.78%0.6%13.02%51.38%127.65%339.39%---53.23%1965.38%-7.23%0.31%0.1%0.05%1.79%1.44%3.3%4.2%31.82%2.08%47.45%52.94%44.67%38%34.62%20.83%4.55%29.17%
Acquisitions0-1.37M0138K10K020M-20.64M0158.45K00000000106.72K-2.91M00000000000
Investments-------------------------------
Other Investing0483K-2.04M6.44M7.03M-1.31M-6.97M20.64M0158.45K-25.4K-234.51K-42.98K-48.39K56.5K2K-4.44K4.44K-106.72K52.9K11K355.27K-418.11K2.94M22.41M0-100K-400K-400K-100K0
Cash from Financing015.43M-907K-3.27M29.64M47.15M22.05M92.27M23.73M28.05M0010.4M9.23M389.63K3.54M-7.72M-3.06M19.75M43.21M9.9M13.29M37.84M25.83M48.33M44.36M28.6M4.7M400K48.4M11.32M
Debt Issued (Net)0000-839K1.25M-1.5M258K326K0000-683.96K-757.47K-8.55M-7.71M-2.98M19.15M-697.03K00-91.84K1.25M1.19M-1.12M2.9M0-100K-400K0
Equity Issued (Net)015M-169K-3.27M32.5M45.1M182K87.99M23.87M28.15M0010.79M01.31M13.09M0-76.95K750.27K43.91M9.9M13.29M37.93M19.41M47.14M45.48M25.7M4.7M500K48.8M0
Dividends Paid0-718K-738K0000000000000000000-1M00000000
Share Repurchases00-278K-3.27M00000008.65M00000-76.95K0000000-3.83M-3.8M00010.94M
Other Financing01.15M00-2.02M805K23.36M4.02M-462.84K-96.51K00-388.87K9.91M-164.96K-1.01M-10.31K0-153.01K0001M5.16M00000011.32M
Net Change in Cash-11.85M-3.62M-30.03M8.41M-18.36M3.44M-30.58M40.71M16.4M21.96M-5.54M-4.46M7.08M6.97M-3.81M-1.43M-10.43M-12.93M8.78M9.49M-9.02M-14.39M10.74M-17.32M16.88M-1.52M-4.8M4.7M400K48.4M6.67M
Free Cash Flow0-29.46M-22.21M-26.7M-42.34M-45.21M-37.26M-50.36M-7.34M-6.25M-5.54M-4.46M-3.32M-2.26M-4.28M-4.96M-10.22M-20.85M-23.63M-21M-14.77M-16.57M-24.28M-46.09M-53.86M-45.89M-37.7M-14.3M-7.6M-2.4M-4.65M
FCF Margin %0%-103.25%-65.55%-61.94%-140.35%-298.61%-902.03%----11608.83%-18804.53%--337.75%-220.43%-134.39%-193.33%-278.81%-319.52%-304.63%-249.52%-3223.76%-1541.22%-3917.81%-2892.66%-1249.74%-754%-275%-158.33%-54.55%-645.83%
FCF Growth %--32.67%16.82%36.94%6.35%-21.33%26%-586.36%-17.46%-12.77%-24.14%-34.44%-46.81%47.16%13.8%51.41%51%11.78%-12.51%-42.23%10.88%31.76%47.32%14.42%-17.37%-21.72%-163.64%-88.16%-216.67%48.39%-4.73%
FCF per Share0.00-1.92-1.66-1.96-3.11-4.09-3.88-5.94-1.19-1.12-1.71-1.56-1.27-1.19-3.63-5.13-12.80-26.52-30.88-32.14-33.72-49.04-89.21-231.60-327.45-314.36-300.48-124.04-69.45-26.95-9.30
FCF Conversion (FCF/Net Income)-0.00x0.74x0.74x0.51x0.73x0.54x0.51x1.04x0.59x0.64x0.77x0.15x0.57x0.15x0.94x0.61x1.24x0.87x1.05x0.42x0.89x1.30x1.24x1.17x1.22x0.91x0.97x0.93x1.02x0.46x0.58x
Interest Paid0000000000000000000000000000000
Taxes Paid001.81M0000000000000000000000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Imminent liquidity and solvency

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2025Q3)

Persistent Disconnect Between Earnings Reality

According to the provided financial data, CASI has consistently reported negative net income over the last ten quarters without generating any positive operating cash flow, suggesting a fundamental inability to convert its commercial activities into tangible liquidity despite the presence of an active product portfolio.

The absence of reported operating cash flow across all periods indicates that the company's cash burn is likely driven by structural operating losses that are not being mitigated by working capital adjustments. Investors should monitor whether this lack of cash generation reflects an inability to collect receivables or simply the overwhelming weight of fixed operating costs.

Free Cash Flow Remains Nonexistent

As reported in quarterly filings, the company has failed to produce positive free cash flow in any of the last ten quarters, with net income losses reaching as high as $14.4 million, highlighting a trajectory that remains deeply entrenched in a cash-burning state.

The consistent failure to achieve positive free cash flow suggests that the current business model is not self-sustaining under existing commercial conditions. This trajectory implies that the company remains entirely dependent on external financing to fund its ongoing research and development and commercial infrastructure.

Hidden Cash Impacts of SBC

Based on the provided cash flow statements, the company has periodically utilized stock-based compensation, such as the $7.2 million recorded in 2023Q4, which serves to obscure the true magnitude of the cash burn by non-cash accounting adjustments that do not improve the underlying liquidity position.

While stock-based compensation is a standard tool for talent retention, its use in a company with no positive operating cash flow warrants further investigation into the dilution impact on shareholders. The reliance on these non-cash adjustments appears to be a mechanism to manage the optics of the income statement while the actual cash position remains under severe pressure.

Capital Allocation Constrained by Burn

As indicated by the lack of dividends, buybacks, or acquisitions in the provided data, CASI's capital deployment is entirely focused on survival, with all available resources directed toward covering operating losses rather than returning value to shareholders or pursuing strategic growth through inorganic means.

The absence of capital deployment activities suggests that management is currently in a defensive posture, prioritizing the preservation of the remaining $13.4 million cash balance. This lack of strategic investment may limit the company's ability to pivot or scale its pipeline, potentially leaving it vulnerable to competitive displacement.

CASI — Frequently Asked Questions

Quick answers to the most common questions about buying CASI stock.

How much cash does CASI Pharmaceuticals, Inc. (CASI) generate from operations?

CASI Pharmaceuticals, Inc. (CASI) generated $-29.2M in net cash from operating activities in 2024. This reflects the cash generated directly from core business operations.

What is CASI Pharmaceuticals, Inc.'s free cash flow?

CASI Pharmaceuticals, Inc. (CASI) reported negative free cash flow of $29.5M in 2024, indicating capital requirements exceeded cash from operations.

What is CASI Pharmaceuticals, Inc.'s capital expenditure (CapEx)?

CASI Pharmaceuticals, Inc. (CASI) spent $0.2M on capital expenditures in 2024. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.

How does CASI Pharmaceuticals, Inc. distribute cash to shareholders?

In 2024, CASI Pharmaceuticals, Inc. (CASI) returned $0.7M to shareholders via cash dividends. This shows the company's commitment to returning capital to its equity investors.